QPRT also exhibited increased expression (p < 0.05) specifically at acquired resistance of EGFR inhibitor treatment (i.e., the analog of clinical PD) in our in vitro model using PC9 cells (Figure 3L), reinforcing the assertion that this pathway is indicative of cancer progression under the selective pressure of treatment. The gene discussed is EGFR; the disease is cancer.